Speaker Details

Jeffrey Phillip Callen, MD, FAAD

Jeffrey Phillip Callen, MD, FAAD

SESSIONS

F008 Managing Tough Real Life Dermatology Cases
Mar 8, 2024 9:00 AM - 11:00 AM Room 30B
S005 Journal Watching
Mar 8, 2024 9:00 AM - 12:00 PM Room 28B
S023 Skinternal Medicine: An Update on Cutaneous Manifestations of Systemic Disease
Mar 8, 2024 1:00 PM - 4:00 PM Room 30D
S059 The Best of American and European Dermatology
Mar 11, 2024 1:00 PM - 4:00 PM Room 6F

HANDOUTS

Login to view handouts

DISCLOSURES

3M Pharmaceuticals – Stockholder Public Company(No Compensation Received); Abbott Laboratories – Stockholder Public Company(No Compensation Received); AbbVie – Stockholder Public Company(No Compensation Received); Allergan, Inc – Stockholder Public Company(No Compensation Received); Amgen – Stockholder Public Company(No Compensation Received); Biogen – Data Safety Monitoring Board(Honoraria); Celgene – Stockholder Public Company(No Compensation Received); Elsevier Inc. – Other(Other Financial Benefit); EMD Serono – Other(Honoraria); JAMA – Other(No Compensation Received); Johnson and Johnson – Stockholder Public Company(No Compensation Received); Merck & Co., Inc – Stockholder Public Company(No Compensation Received); Pfizer Inc. – Stockholder Public Company(No Compensation Received); Procter & Gamble Company – Stockholder Public Company(No Compensation Received); Proivant – Data Safety Monitoring Board(Fees); UpToDate, Inc. – Other(Honoraria);